Eculizumab

Phase 3

Chugai Pharmaceutical Co., Ltd. (4519.T)

00%

What is LOA?

Phase 3

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Apr '27

4519.TPhase 3$71.1B

Eculizumab Phase 3 Est. Readout

Eculizumab• Paroxysmal Nocturnal Hemoglobinuria190

Apr 2027~Estimated

CT.gov

00%

Competitive Landscape

4 competitors in Paroxysmal Nocturnal Hemoglobinuria

REGNPozelimab + Cemdisiran

Drug Information

Target Indication

Paroxysmal Nocturnal Hemoglobinuria

Clinical Trial

NCT04432584

Last updated: 8/15/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

4519.T

Chugai Pharmaceutical Co., Ltd.

Biotechnology•North America•TSE

Related Pipeline

MTXPhase 3

Rheumatoid Arthritis

ED-71Phase 3

Osteoporosis

peginterferon alfa-2aPhase 3

Chronic Hepatitis C

recombinant human erythropoietinPhase 3

Chemotherapy Induced Anemia

MRA (Tocilizumab)Phase 3

Rheumatoid Arthritis

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts